Rodman & Renshaw assumes coverage on Optimer Pharmaceuticals Inc. (Nasdaq: OPTR) with a Market Outperform rating and $8 price target.
This article: 140 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE